GenSight Biologics reported the appointment of Francoise de Craecker to its Board of Directors, replacing Natalie Mount. de Craecker is joining as an independent Director. According to a media release, in her last position, Mrs. de Craecker led the EMEA (Europe, Middle East & Africa) region at AveXis, further acquired by Novartis. She built from scratch the multifunctional team launching Zolgensma, a one-shot Gene Therapy for the treatment of Spinal Muscular Atrophy, in the EMEA region. Prior to joining AveXis, Mrs. de Craecker was leading European operations for Raptor Pharmaceuticals at the critical phase of a shift from R&D to commercialization of their lead product in Cystinosis.